Period pain is not normal. But because of undiagnosed endometriosis, it’s a reality for 190 million women globally. At EndoGene.bio, we will be helping women across the world get access to early diagnosis through cutting-edge epigenetics.
Endometriosis affects 10% of women, takes 7 years to diagnose and has high societal and economic costs. In the EU and US alone, the estimated cost of delayed diagnosis reaches €300B.
This is caused by a lack of specific and early tests. At EndoGene.Bio, we are developing a prescription diagnostic test based on epigenetic biomarkers found in menstrual blood that patients can take in the comfort of their home.
With this technology, we will reduce time to diagnosis from 7 years to two consultations: one to get your test done, one to get your results.
Maria Teresa Perez Zaballos
Ex-Merck Fertility Portfolio Expansion Manager. PhD in Medical Devices, & MSc in Biotech Management
PhD & Post-Doc in Genetics & Epigenetics with extensive stem cell experience ex-Université de Paris